Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23393883 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL1763291 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL13363848 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL1763221 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL13436114 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL14065400 | 0.90 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL4865057 | 0.90 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL6924404 | 0.90 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL11468464 | 0.87 | MEN1 (0.45) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL19283462 | 0.86 | MEN1 (0.64) | MEN1KMT2APRCPKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | claimed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | claimed |
| WO-2025089237-A1 | ADHESIVE COMPOSITION, CONNECTION STRUCTURE, AND METHOD FOR PRODUCING CONNECTION STRUCTURE | 株式会社レゾナック | 2025-05-01 | — | — | WO | disclosed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-111032047-B | Method for producing optically active compound | 多特疗法-1公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| US-11561471-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-01-24 | — | — | US | disclosed |
| US-11543749-B2 | Resist composition and method for producing resist pattern, and method for producing plated molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210278765-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN, AND METHOD FOR PRODUCING PLATED MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| US-10969685-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| CN-107001799-B | Resin composition, solid-state imaging device using the same, and method for manufacturing the same | 东丽株式会社 | 2020-11-27 | — | — | CN | disclosed |
| WO-2010003226-A1 | CHIRAL ACYCLIC DIAMINOCARBENE LIGANDS, PRECURSORS THEREFORE AND THEIR USE IN ORGANIC SYNTHESIS REACTIONS | THADANI AVINASH N (CA) | 2010-01-14 | — | — | WO | disclosed |
| US-7479574-B2 | Method of producing macrocyclic ketone, and intermediate thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-01-20 | — | — | US | disclosed |
| US-7423059-B2 | Pharmaceutically active compounds and methods of use | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1845078-A1 | PROCESS FOR PRODUCING LARGE CYCLIC KETONE AND INTERMEDIATE THEREFOR | Takasago International Corporation (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-0930312-B1 | Production method of optically active amino alcohols | JAPAN TOBACCO INC (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6197966-B1 | REACTING MESOEPOXIDE WITH AMINE TO FORM 1,3-DIOXEPANE DERIVATIVE; ACID CATALYSIS; RING CONTRACTION TO 1,3-DIOXOLANE | JAPAN TOBACCO INC. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0930312-A1 | Production method of optically active amino alcohols | Japan Tobacco Inc. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287870-A1 | Method of Producing Macrocyclic Ketone, and Intermediate Thereof | MSMO1, CYP17A1, DNMT1 | MEN1 57/4885KMT2A 553/4885SLC18A3 598/4885 |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | FTH1, FECH, HCCS | MEN1 2070/4885KMT2A 624/4885SLC18A3 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.